A report released today by Maxim Group about Cellular Biomedicine (NASDAQ:CBMG) bumps the target price to $18.00
- Updated: November 29, 2016
Just yesterday Cellular Biomedicine (NASDAQ:CBMG) traded -2.11% lower at $14.20. Cellular Biomedicine’s 50-day average is $13.29 and its two hundred day average is $14.06. With the last stock price up -1.14% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.03% over the date range. Volume of trade was up over the average, with 31,498 shares of CBMG changing hands over the typical 20,269
In a report released on 11/29/2016 Maxim Group raised the target price of Cellular Biomedicine (NASDAQ:CBMG) from $16.00 to $18.00 reporting a possible upside of 0.27%.
On 09/22/2016, Maxim Group released a statement for Cellular Biomedicine (NASDAQ:CBMG) upped the target price from $0.00 to $16.00. At the time, this indicated a possible upside of 0.12%.
With a total market value of $0, Cellular Biomedicine has with a one year low of $10.44 and a one year high of $23.68 .
Brief Synopsis About Cellular Biomedicine (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company's technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.